Valerio Therapeutics SA
ENXTPA:ALVIO
France / Healthcare / Biotechnology
Exchange Data
Hide this widget
Price
0.06 EUR
Day change
0.00 (-5.83%)
52-week range
0.04 - 0.14
10:52 - Real Time Data
Summary of Valerio Therapeutics SA
Hide this widget
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies target...
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Year
10 Years
- (-)
Data Explorer
Hide this widget
Data could not be retrieved
Peer Benchmarks
Hide this widget
Quote
Value
Size
Growth
Profit
| ALVIO | Peers | Sector | |
|---|---|---|---|
Market Cap | 10.301 M | 61.268 M | 57.248 M |
Price % of 52 Week High | 47.9% | 47.7% | 62.4% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | 3.7% | -0.5% | -0.7% |
1 Year Price Total Return | -41.8% | -43.6% | -11.7% |
Beta (5 Year) | 1.86 | 0.88 | 0.64 |
In the News
Hide this widget
Fair Value
Hide this widget
Average
0.07
Upside
8.2%
Uncertainty
HIGH
Spread
0.04 - 0.09
Market Range
52 weeks
€0
€0
€0.063
Analyst Targets
0 analysts
-
Investing Models
€0
€0
€0.068
Financial Health
Health Details
Hide this widget
Financial Health for Valerio Therapeutics is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.
12345
Weak Performance
▼
▼
Financial Models for Valerio Therapeutics SA
Model Gallery
Hide this widget
| 10Y DCF Revenue ExitView Updated 19 hours ago |
| 5Y DCF Revenue ExitView Updated 19 hours ago |
| DuPont ROE AnalysisView Updated 3 days ago |
| Earnings Power ValueView Updated 19 hours ago |
| 10Y Historical FinancialsView Updated 3 days ago |
| 5Y Historical FinancialsView Updated 3 days ago |
| P/E MultiplesView Updated 19 hours ago |
| Price / Book MultiplesView Updated 19 hours ago |
| Price / Sales MultiplesView Updated 19 hours ago |
| EV / Revenue MultiplesView Updated 19 hours ago |
| CAPM WACC ModelView Updated 8 hours ago |
| 10Y DCF EBITDA ExitView Updated 19 hours ago |
| 10Y DCF Growth ExitView Updated 19 hours ago |
| 5Y DCF EBITDA ExitView Updated 19 hours ago |
| 5Y DCF Growth ExitView Updated 19 hours ago |
| EV / EBIT MultiplesView Updated 19 hours ago |
| EV / EBITDA MultiplesView Updated 19 hours ago |
Historical Financials
Full Financials
Hide this widget
| (EUR in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Jun-24 | Jun-23 | Jun-24 |
| Income Statement | |||||
| Revenue | 1.44 | 1.80 | 1.89 | 0.04 | |
| Operating Income | (17) | (19) | (18) | (6.01) | (5.46) |
| Net Profit | (20) | (20) | (20) | (5.82) | (5.48) |
| Diluted EPS | -0.18 | -0.15 | -0.12 | -0.050 | -0.033 |
| EBITDA | (17) | (19) | (16) | (5.94) | (4.71) |
| Balance Sheet | |||||
| Cash & ST Invest. | 15 | 6.82 | 4.00 | 17 | 4.00 |
| Current Assets | 21 | 13 | 8.73 | 22 | 8.73 |
| Total Assets | 43 | 35 | 29 | 44 | 29 |
| Current Liabilities | 7.15 | 11 | 9.70 | 12 | 9.70 |
| Total Liabilities | 21 | 20 | 25 | 21 | 25 |
| Total Equity | 22 | 15 | 4.02 | 23 | 4.02 |
| Total Debt | 10 | 11 | 13 | 14 | 13 |
| Cash Flow Statement | |||||
| Cash Flow Operations | (9.44) | (19) | (16) | (4.56) | (3.42) |
| Cash From Investing | (0.41) | (0.18) | (0.12) | (0.05) | (0.02) |
| Cash From Financing | 6.46 | 11 | 3.50 | 5.72 | 2.09 |
| Free Cash Flow | (9.93) | (19) | (16) | (4.61) | (3.44) |